Questions

807. Deputy Conor Sheehan asked the Minister for Health when the current review of the core list of medications under the long-term illness scheme will be completed; the way in which a drug can be put forward for consideration under this review; and if she will make a statement on the matter. [49053/26]

902. Deputy Conor Sheehan asked the Minister for Health if the NCPE is evaluating the application of mounjaro and wegovy for severe metabolic and endocrine conditions alongside obesity; and if she will make a statement on the matter. [49595/26]

903. Deputy Conor Sheehan asked the Minister for Health the number of validated applications submitted by clinicians for Glucagon-like peptide-1, GLP-1, therapies under the drugs payment scheme that were rejected by the primary care reimbursement service, PCRS, system on account of diabetes only automated controls; and if she will make a statement on the matter. [49596/26]

729. Deputy Conor Sheehan asked the Minister for Health if she plans to broaden the reimbursement criteria for GLP-1 medications, such as ozempic, under the drugs payment scheme or long-term illness scheme to include patients diagnosed with metabolic disorders, including polycystic metabolic syndrome and polycystic ovary syndrome, where insulin resistance is a core clinical symptom; her views on whether she intends t…

821. Deputy Conor Sheehan asked the Minister for Health the reason Skyclarys is not included on the agenda for the upcoming HSE drugs group meeting; if this drug will be put on the agenda for this meeting; and if she will make a statement on the matter. [44885/26]

270. Deputy Conor Sheehan asked the Minister for Health the criteria used to determine eligibility for specific medications to treat Parkinson’s disease on the long-term illness scheme; the frequency with which the list is reviewed to include new medications; when the next review will take place; and if she will make a statement on the matter. [44516/26]

288. Deputy Conor Sheehan asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of Risdiplam for adults living with spinal muscular atrophy (SMA); and if she will make a statement on the matter. [38242/26]

1983. Deputy Conor Sheehan asked the Minister for Health for an update on the negotiations around the inclusion of the shingles vaccine in the national immunisation programme; when she will make a decision on whether to include the shingles vaccine in the national immunisation programme; and if she will make a statement on the matter. [19852/26]

525. Deputy Conor Sheehan asked the Minister for Health the specific steps being taken to ensure the HSE considers the time-critical nature of Friedreich’s ataxia during the current price negotiations for Skyclarys, the only drug approved for treatment of this condition, given the 570 days since the application for use was lodged and the rapid progression of the disease in sufferers; and if she will make a statement …

526. Deputy Conor Sheehan asked the Minister for Health the way in which the commitments in the National Rare Disease Strategy 2025 – 2030 are being applied to the approval process for the drug Skyclarys used to treat Friedrich's ataxia to prevent further delays in addressing the unmet need of sufferers; and if she will make a statement on the matter. [17918/26]

527. Deputy Conor Sheehan asked the Minister for Health the way in which the 2026 IPHA Framework Agreement on access to new and innovative medicines which aims for a 180-day decision timeline is being applied to the drug Skyclarys used to treat Friedrich's ataxia to prevent further delays in addressing the unmet need of sufferers; and if she will make a statement on the matter. [17919/26]

593. Deputy Conor Sheehan asked the Minister for Health the number of persons prescribed the weight loss drug ozempic, by county from 2023 to date in 2025, in tabular form. [67730/25]

594. Deputy Conor Sheehan asked the Minister for Health the number of persons prescribed the weight loss drug mounjaro, by county, from 2023 to date in 2025, in tabular form. [67731/25]

965. Deputy Conor Sheehan asked the Minister for Health her plans to roll out a long-acting injection to prevent HIV, as was done by NHS England recently; and if she will make a statement on the matter. [61225/25]

2142. Deputy Conor Sheehan asked the Minister for Health if she is aware of difficulties that have arisen with transgender women accessing the free HRT scheme; and if she will make a statement on the matter. [44850/25]

3023. Deputy Conor Sheehan asked the Minister for Health the action she proposes to take to deal with the unregulated operators in the cosmetics industry; and if she will make a statement on the matter. [42870/25]

3024. Deputy Conor Sheehan asked the Minister for Health if she intends to introduce licensing for non-surgical cosmetic procedures; the form that licensing would take; and if she will make a statement on the matter. [42871/25]

3025. Deputy Conor Sheehan asked the Minister for Health for an update on The Patient Safety (Licensing) Bill 2017, including when the legislation will be referred back to her from the Attorney General’s office; a timeline for enactment; and if she will make a statement on the matter. [42872/25]

3026. Deputy Conor Sheehan asked the Minister for Health if she will update the licensing for the administration of a treatment (details supplied) to allow nurses to administer; and if she will make a statement on the matter. [42873/25]

534. Deputy Conor Sheehan asked the Minister for Health if she will examine and expedite the approval of a new drug givinostat which has been approved in the UK and US for the treatment of Duchenne muscular dystrophy; and if she will make a statement on the matter. [31509/25]

674. Deputy Conor Sheehan asked the Minister for Health if weight-loss drugs such as ozempic and mounjaro will be made available to medical card patients; her views on whether they should; and if she will make a statement on the matter. [28848/25]